Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
11.02
0.00 (0.00%)
Jul 16, 2025, 4:00 PM - Market closed
Verve Therapeutics Revenue
Verve Therapeutics had revenue of $32.98M in the quarter ending March 31, 2025, with 479.03% growth. This brings the company's revenue in the last twelve months to $59.61M, up 271.44% year-over-year. In the year 2024, Verve Therapeutics had annual revenue of $32.33M with 174.98% growth.
Revenue (ttm)
$59.61M
Revenue Growth
+271.44%
P/S Ratio
15.92
Revenue / Employee
$217,566
Employees
274
Market Cap
984.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VERV News
- 4 weeks ago - VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 4 weeks ago - Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ
- 4 weeks ago - Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - Reuters
- 4 weeks ago - Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PRNewsWire
- 4 weeks ago - Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - Barrons
- 4 weeks ago - Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - Reuters
- 6 weeks ago - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire